
From the Annual Conference of the European Society of Human Reproduction and Embryology in Rome

From the Annual Conference of the European Society of Human Reproduction and Embryology in Rome

Follicle stimulating hormone (FSH) and anti-Müllerian hormone (AMH) represent the two most frequently utilized laboratory tests in determining ovarian reserve (OR). This study determined the clinical significance of their concordance and discordance in female infertility patients.

Over the past 12 years, it has become increasingly recognized that insulin resistance is central to the pathogenesis of the polycystic ovarian syndrome (PCOS). The use of insulin-sensitizing agents, such as Metformin, a biguanide insulin-lowering agent in ovulation induction for IVF, has been widely studied.

Effective health policy requires a thorough understanding of intrinsic social, ethical, political and philosophical aspects of infertility and its treatment. The procedure with the highest success rate to address the clinical challenge of infertility for many patients is a relatively high-technology procedure, in vitro fertilisation (IVF).

Celiac disease occurs in roughly 1% of all humans. It is an autoimmune condition initially caused by hypersensitivity and hyperimmunity to a class of proteins, called gliadins, which are found in the outer husk of common grains such as wheat, barley, rye, and oats.

1. What is your most interesting case of celiac disease? 2. How common is celiac disease in women with amenorrhea? 3. If a woman is diagnosed with celiac disease, should she be screened for any other conditions?

My name is Joachim Dudenhausen and I am Professor of Obstetrics and Head of the Department of Obstetrics of the Charity University Medical School in Berlin. The institution is the biggest obstetrical department in Germany with 6,000 deliveries per year with a high rate in high risk pregnancies like, diabetes, malformation, pre-term labor, multiples and so on.

Coverage of the 2009 World Congress of Perinatal Medicine

Coverage of the 2009 World Congress of Perinatal Medicine

Coverage of the 2009 World Congress of Perinatal Medicine

Coverage of the 2009 World Congress of Perinatal Medicine

Coverage of the 2009 World Congress of Perinatal Medicine

A Fact Sheet From The Center For Applied Reproductive Science

The statistics are shocking: One in seven US women will be treated for pelvic inflammatory disease (PID) over the course of her lifetime. That translates into more than a million women diagnosed with PID each year.

Obesity before pregnancy is associated with an increased risk of several adverse outcomes of pregnancy. The risk profiles among lean, normal, or mildly overweight women are not, however, well established.

Fertilization, both natural and by assisted reproduction techniques (ART), needs the dual support of the sperm not only for the messages it carries but for being as a messenger cell the and carrier of these messages as well.

Coverage from the 28th annual meeting of the Society for Maternal-Fetal Medicine

Coverage from the 28th annual meeting of the Society for Maternal-Fetal Medicine

Coverage from the 28th annual meeting of the Society for Maternal-Fetal Medicine

Coverage from the 28th annual meeting of the Society for Maternal-Fetal Medicine

Coverage from the 28th annual meeting of the Society for Maternal-Fetal Medicine

Q: A request for Information about Premenopause osteoporosis. I am a 31 year old woman and after the birth of my second child 4 months ago have had back pain. After an x-ray that showed a collapse in one part of my spine, I was sent for a bone density test. At the test they took my height and I was 2 inches shorter. I'm looking for information on pre menopause osteoporosis and can find very little. I would like to be informed on what can be done to help me before I go over my test results with my doctor and to better understand my options. Can you help?

Questions this month have been answered by:R. Wayne Whitted, MD., MPH, OBGYN.net Editorial Advisor

Coverage of 36th AAGL Congress November 2007, Washington, DC

This month's questions answered by:Harvey S. Marchbein, MD, Chairman,OBGYN.net Osteoporosis Editorial Advisory Board